Patients who are immunocompromised generally had worse risk and severity of CDI.

Clostridioides difficile (C. diff.) infection (CDI) is a leading cause of hospital acquired diarrhea in North America and Europe and a major cause of morbidity and mortality. Known risk factors do not fully explain CDI susceptibility, and genetic susceptibility is suggested by the fact that some pat …

The development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many patients do not respond or gradually lose their response, necessitating the search for other therapeutic strategies (1). In this clinical case, we describe …

Thiopeptides exhibit potent antimicrobial activity against Gram-positive pathogens by inhibiting bacterial protein synthesis. Micrococcins are among the structurally simpler thiopeptides, but they have not been exploited in detail. This research involved a computational simulation of micrococcin P2 …

When implementing healthcare innovations, clinical implementation coordinators facilitated the implementation process through their roles and responsibilities and acted as strategic partners in improving the adoption and sustainability of a fluoroquinolone preauthorization protocol.

In recent years there has been increasing interest in the empowerment of patients to serve as partners in efforts to prevent healthcare-associated infections. However, patients often have limited awareness of the risk for acquisition and dissemination of healthcare-associated pathogens and have rece …

HBO may have beneficial effect on CDI by shortening the symptomatic period and preventing recurrence.

The patient advocacy organization has events in place and is ready to launch its annual C diff awareness campaign.

Clostridioides difficile is an anaerobic spore-forming Gram-positive bacterium. C. difficile carriage and 16S rDNA profiling were studied in three clinical groups at three different sampling times: inflammatory bowel disease (IBD) patients, C. difficile infection (CDI) patients …

Clostridioides difficile infection (CDI) may recur in approximately 10-30% of patients, and the risk of recurrence increases with each successive recurrence, reaching up to 65%. C. difficile can form biofilm with approximately 20% of the bacterial genome expressed differently between b …

Clostridioides difficile is the most important pathogen causing antimicrobial-associated diarrhea and has recently been recognized as a cause of community-associated C. difficile infection (CA-CDI). This study aimed to characterize virulence factors, antimicrobial resistance (AMR), rib …

Clostridioides difficile infection is expected to become the most common healthcare-associated infection worldwide. C. difficile-induced pathogenicity is significantly attributed to its enterotoxin, TcdA, which primarily targets Rho-GTPases involved in regulating cytoskeletal and tight …

Clostridioides difficile is a predominant nosocomial pathogen within the healthcare setting able to produce biofilms. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics trigger mechanisms affecting bacterial virulence, including increased adhesion and biofilm formation. The aim o …

Though antibiotics are the mainstay treatment for Clostridioides difficile, a large population of individuals infected will experience recurrence. In turn, fecal microbiota transplantation (FMT) has emerged as a promising treatment for recurrent C. difficile infection (rCDI). Mechanist …

Clostridioides difficile infection (CDI) has been increasingly observed in children, but there is a lack of epidemiological and molecular data on CDI in Latin America. This prospective cohort study aimed to investigate the role of CDI in children with diarrhea. It included 105 children with antimicr …

BACKGROUND Clostridioides difficile (C. difficile) is a bacterium that is well known for causing serious diarrheal infections and can even lead to colon cancer if left untreated. Disruption of the normal healthy bacteria in the colon can lead to development of C. difficile colitis. Risk factors for …

Health care facility floors and sink drains and other wastewater drainage sites are universally contaminated with potential pathogens and there are plausible mechanisms by which organisms can be disseminated from these sites. However, floors and sink drains are not addressed as potential sources of …

Clostridioides difficile (C. diff.) infection (CDI) is a leading cause of hospital acquired diarrhea in North America and Europe and a major cause of morbidity and mortality. Known risk factors do not fully explain CDI susceptibility, and genetic susceptibility is suggested by the fact that some pat …

The 31-year-old, from Houston, was diagnosed with C. diff, a highly contagious infection that throws the digestive system off balance and leads to painful inflammation in the colon.

Lab experiments support treating inflammation rather than bacteria

A chemical engineer at the University of Alberta has developed a disinfectant that is more effective than purely alcohol-based products, just by adding salt.

If you have UC, you’re more susceptible to this serious infection. Here’s what you need to know to protect yourself.

While inflammation is involved in both of these conditions, they have some important distinctions.

Clostridioides difficile (C. diff) intestinal infections can cause severe, debilitating diarrhea in patients who are hospitalized or on immunosuppressive therapies. The infections can be very hard to ...

New phase 1B data support further investigation into Adiso Therapeutic's prospective treatment.

The following is a summary of “Does clinician-initiated Clostridioides difficile testing improve outcomes of patients with Clostridioides Difficile infection?” published in the October 2023 issue of Infectious Control by Bartlett, et al. Clostridioides difficile (C. difficile) is a common illness that people get in hospitals. It can have serious effects on patients and our healthcare

LITTLE RIVER, SC, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - PCT LTD (“PCTL” OTC Pink): Paradigm Convergence Technologies Corp (a Subsidiary of PCTL) manufactures, sells and leases equipment which produce a variety of EPA approved, eco-friendly disinfectant and degreaser fluids, is proud to announce its partnership with HypoClean, LLC a Colorado corporation specializing in hypochlorous acid (HOCl) technology and Veteran Commercial Cleaning, LCC, a global professional, commercial cleani

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.

The effectiveness of fecal microbiota transplantation (FMT) in ulcerative colitis (UC) remains unclear. This study aimed to investigate the feasibility and effectiveness of serial fecal infusions via colonoscopy in patients with active UC. Subjects with mild-to-moderate UC received three consecutive …

These data suggest that IBD patients, potentially due to underlying intestinal dysbiosis, experience undiagnosed C. difficile infections that result in impaired toxin-specific immunity. This may contribute to the development of inflammatory T cell responses toward commensal bacteria and provide a ra …